Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine
(3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress
neurodegeneration, and assess safety and tolerability in patients with early stage
Alzheimer's disease. This study will provide the initial data on target engagement and
Alzheimer's disease-relevant outcomes for future trials.